Sign inJoin waitlistJoin the waitlist

Daniel Halperin

Vice Chair for Clinical Affairs · Emory University School of Medicine

Credentials: · · · · ·

History

Emory University School of Medicine
Present
Emory University School of Medicine
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2012–2015
Internal Medicine
Brigham and Women's Hospital
2009–2010
Weill Cornell Medicine
2005–2009

Research

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
JAMA Oncology · 2017 · 2,789 citations
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 538 citations
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation
Proceedings of the National Academy of Sciences of the United States of America · 2002 · 492 citations

James Yao
40 papers
Arvind Dasari
33 papers
Thor Halfdanarson
10 papers
Jennifer Chan
9 papers
Emily Bergsland
7 papers
JS
Jonathan Strosberg
7 papers
Pamela Kunz
7 papers · 4 as a resident
Priya Bhosale
7 papers
Jeffrey Lee
6 papers
Jessica Maxwell
6 papers · 1 as a fellow
Matthew Katz
6 papers
Scott Woodman
6 papers

Clinical trials

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2021
Chromogranin A as Blood Marker in Cancer Patients
Principal investigator · Completed
Brahms AG
2019–2021
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2014–2018
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Site PI · Recruiting · Phase 1, Phase 2
Chimeric Therapeutics
2024–2027